🔗 Share this article The Global Health Body Raises Concern Over Acute Lack of Weight-Loss Injections Fewer than 10% of people eligible to benefit from weight-loss injections like Wegovy have access to them, warns the global health agency as it issues its inaugural recommendations on the drugs. Considering over a billion individuals worldwide now obese, it is urging more widespread and fairer access to GLP-1 medication. According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken. "Our latest guidelines acknowledges that excess weight is a long-term condition that can be treated with comprehensive and continuous treatment," said its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and supply-chain constraints are major barriers to broad access to the treatments that can assist patients in reducing significant body mass, notes the organization. GLP-1 Therapy Scarcity Despite the current most favorable case, the supply of GLP-1 therapies could only cover about 100 million people – under 10% of the global need, as stated by the WHO. The guideline encourages nations and manufacturers to widen access, through strategies such as voluntary licensing. Exclusive production rights on a key compound – the main component of the drug Wegovy – is scheduled to end in several countries in 2026. How Obesity Injections Function The injections replicate a natural hormone to delay gastric emptying, curb appetite and boost the sense of being full so people consume fewer calories. Patients typically begin shedding pounds after several weeks of starting on the regular doses. Studies points to people may regain a significant portion a year later of discontinuing the medication, when their typical appetite return. Being overweight or obese increases your likelihood for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and specific cancers. Excess weight impacts people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
Fewer than 10% of people eligible to benefit from weight-loss injections like Wegovy have access to them, warns the global health agency as it issues its inaugural recommendations on the drugs. Considering over a billion individuals worldwide now obese, it is urging more widespread and fairer access to GLP-1 medication. According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken. "Our latest guidelines acknowledges that excess weight is a long-term condition that can be treated with comprehensive and continuous treatment," said its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and supply-chain constraints are major barriers to broad access to the treatments that can assist patients in reducing significant body mass, notes the organization. GLP-1 Therapy Scarcity Despite the current most favorable case, the supply of GLP-1 therapies could only cover about 100 million people – under 10% of the global need, as stated by the WHO. The guideline encourages nations and manufacturers to widen access, through strategies such as voluntary licensing. Exclusive production rights on a key compound – the main component of the drug Wegovy – is scheduled to end in several countries in 2026. How Obesity Injections Function The injections replicate a natural hormone to delay gastric emptying, curb appetite and boost the sense of being full so people consume fewer calories. Patients typically begin shedding pounds after several weeks of starting on the regular doses. Studies points to people may regain a significant portion a year later of discontinuing the medication, when their typical appetite return. Being overweight or obese increases your likelihood for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and specific cancers. Excess weight impacts people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.